Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADMP Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Adamis Pharmaceuticals Stock (NASDAQ:ADMP) 30 days 90 days 365 days Advanced Chart Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Adamis Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.77▼$3.9952-Week Range N/AVolume119,800 shsAverage Volume811,695 shsMarket Capitalization$7.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMP Stock News HeadlinesDMK Pharmaceuticals Corp DMKNovember 8, 2023 | morningstar.comAdamis changes name to DMK Pharmaceuticals, ticker to DMKSeptember 7, 2023 | msn.comBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.November 4, 2024 | Brownstone Research (Ad)Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic FocusSeptember 7, 2023 | finance.yahoo.comAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 21, 2023 | finanznachrichten.deAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 21, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAugust 4, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Pricing of $8.0 Million Public OfferingAugust 2, 2023 | finance.yahoo.comSee More Headlines ADMP Stock Analysis - Frequently Asked Questions How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Co. (NASDAQ:ADMP) released its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%. When did Adamis Pharmaceuticals' stock split? Adamis Pharmaceuticals shares reverse split before market open on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adamis Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and FuelCell Energy (FCEL). Company Calendar Last Earnings3/31/2022Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:ADMP CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone(858) 997-2400FaxN/AEmployees11Year Founded2006Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-502.73% Pretax Margin-471.80% Return on Equity-420.53% Return on Assets-256.87% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.19 Sales & Book Value Annual Sales$4.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.26) per share Price / BookN/AMiscellaneous Outstanding Shares9,360,000Free Float9,237,000Market Cap$7.26 million OptionableOptionable Beta1.27 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ADMP) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adamis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.